Mr. Andre Larente reports

DIAGNOS ANNOUNCES A 3-YEAR PARTNERSHIP AGREEMENT WITH THE UNIVERSITY OF MONTREAL HOSPITAL CENTRE (CHUM) ON THE USE OF ARTIFICIAL INTELLIGENCE

Diagnos Inc. has signed a three-year framework partnership agreement with the CHUM (Center Hospitalier de l'Universite de Montreal/University of Montreal Hospital Centre) on AI (artificial intelligence) projects applied to the early detection of various retinal diseases.

The various algorithms developed by Diagnos will be used to analyze changes in retinal microcirculation and their impacts on the prevention of complications of cardiovascular disease. This agreement also supports the company's project to screen diabetic retinopathy with automatic detection assisted by artificial intelligence, launched in June, 2018. As soon as sanitary conditions permit, the technological showcase will resume in the endocrinology (diabetes) and ophthalmology clinics of the CHUM in order to complete its demonstration phase.

"We are pleased to be working with Diagnos to bring innovation and excellence in care to patients. The evaluation and refinement of Diagnos's technology using artificial intelligence in the early detection of certain diseases by our ophthalmology, endocrinology and now cardiology teams contribute to improving the quality and safety of the care provided to the population," said Dr. Fabrice Brunet, president and chief executive officer of the CHUM.

"Diagnos would like to thank the CHUM for its support in demonstrating our technologies and also for the rigorous work on the evaluation of the performance and safety of our CARA platform. We have different projects that will allow us to develop several innovations in AI with the analysis of the retina. These new developments in early detection of diseases will have a low cost and a non-invasive methodology for patients," said Andre Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a public Canadian company dedicated to early detection of health problems based on its FLAIRE artificial intelligence (AI) platform. The use of the FLAIRE platform allows for rapidly modifying and developing applications such as CARA (computer-assisted retina analysis). CARA's artificial-intelligence-based image enhancement algorithms provide sharper, clearer and easier-to-analyze traditional retinal images. CARA is a cost-effective tool for real-time screening in a large number of patients. CARA has been approved by a number of regulators, including Canada (Health Canada), the United States (the U.S. Food and Drug Administration), Mexico (COFEPRIS) and Europe (EC).

We seek Safe Harbor.